Interferon-α
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2026-09-01 — Type-I interferon-activated NK cells control polycythemia vera in vivo.: Preclinical (in vivo mouse PV model): type-I IFN’s therapeutic effect requires NK cells, which preferentially kill JAK2V617F-mutant HSPCs in a TNF-α-dependent manner; basal IFN sensing by NK cells also provides ongoing immune surveillance that restrains MPN even without exogenous IFN-α. (novelty: 5)
Open questions
Related
Contributing findings
Type-I interferon-activated NK cells control polycythemia vera in vivo.
01-sep-2026
novelty 5
per-area 5
strengthens